Literature DB >> 16644055

Elevated temperature accelerated release testing of PLGA microspheres.

Banu S Zolnik1, Pauline E Leary, Diane J Burgess.   

Abstract

Drug release from four different poly(lactic-co-glycolic) acid (PLGA) microsphere formulations was evaluated under "real-time" (37 degrees C) and accelerated release testing conditions of elevated temperature (45, 53, 60 and 70 degrees C) and increase in flow rate (4-35 ml/min) using United States Pharmacopeia (USP) apparatus 4. Formulation 5 K (composed of low Mw PLGA) exhibited diffusion-controlled kinetics in "real-time". Whereas, formulations 25 K, 28 K and 70 K (composed of medium and high Mw PLGA) followed erosion-controlled kinetics at 37 degrees C. Temperature-induced degradation of the microspheres was studied by monitoring drug release rates, change in molecular weight and morphological changes. Drug release rates at elevated temperature were used to predict "real-time" release applying the Arrhenius equation. The energy of activation for dexamethasone release from PLGA microspheres was calculated as 19.14 kcal/mol. Molecular weight change measured by gel permeation chromatography followed first order kinetics for both "real-time" and accelerated release. All four formulations exhibited morphological changes (such as surface pore closing and geometry change) at elevated temperature with consequent reduction in burst release.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644055     DOI: 10.1016/j.jconrel.2006.02.015

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  41 in total

1.  Influence of process and formulation parameters on dissolution and stability characteristics of Kollidon® VA 64 hot-melt extrudates.

Authors:  Sindhuri Maddineni; Sunil Kumar Battu; Joe Morott; Soumyajit Majumdar; S N Murthy; Michael A Repka
Journal:  AAPS PharmSciTech       Date:  2014-11-01       Impact factor: 3.246

Review 2.  In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?

Authors:  Jie Shen; Diane J Burgess
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

Review 3.  Hybrid nanoparticles for detection and treatment of cancer.

Authors:  Michael J Sailor; Ji-Ho Park
Journal:  Adv Mater       Date:  2012-05-21       Impact factor: 30.849

4.  Droplet based microfluidic fabrication of designer microparticles for encapsulation applications.

Authors:  Tiantian Kong; Jun Wu; Michael To; Kelvin Wai Kwok Yeung; Ho Cheung Shum; Liqiu Wang
Journal:  Biomicrofluidics       Date:  2012-07-20       Impact factor: 2.800

5.  Microspheres prepared with PLGA blends for delivery of dexamethasone for implantable medical devices.

Authors:  Yan Wang; Bing Gu; Diane J Burgess
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

6.  Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings.

Authors:  Jie Shen; Diane J Burgess
Journal:  Int J Pharm       Date:  2011-10-13       Impact factor: 5.875

7.  Stability studies of microparticulate system with piroxicam as model drug.

Authors:  Shivanand Puthli; Pradeep R Vavia
Journal:  AAPS PharmSciTech       Date:  2009-07-01       Impact factor: 3.246

8.  Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.

Authors:  Rajkumar Malayandi; Phani Krishna Kondamudi; P K Ruby; Deepika Aggarwal
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

9.  Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation.

Authors:  Srinivas Rao Chennamaneni; Christina Mamalis; Bonnie Archer; Zack Oakey; Balamurali K Ambati
Journal:  J Control Release       Date:  2013-01-13       Impact factor: 9.776

10.  Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice.

Authors:  Maha Fadel; Kawser Kassab; Doa Abdel Fadeel
Journal:  Lasers Med Sci       Date:  2010-03       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.